CAR T-cell therapy
Since it was approved by the U.S. Food and Drug Administration (FDA) in the fall of 2017, a form of the powerful and promising therapy known as CAR T-cell therapy has been used to treat certain young patients with B-cell acute lymphoblastic leukemia (ALL) who have relapsed or didn’t respond to standard regimens. Today, researchers … Continued
Jerry Jalbert is always up for new adventures. He did not expect that non-Hodgkin lymphoma (NHL) would be one of them, but with the help of CAR T-cell therapy that keeps his cancer at bay, the 73-year-old professional photographer-turned-baker-turned-forest checkpoint operator is continuing to enjoy life’s many journeys alongside his wife, Ethel. “We are not … Continued
In May 2018, Tyler Goodwin underwent CAR T-cell therapy for follicular non-Hodgkin lymphoma (NHL). While he was having preparatory chemotherapy for the procedure, a surprise visitor to his hospital bedside provided a powerful reminder of why this promising new cancer treatment was so important to him. “It was my daughter Theresa, all made up for … Continued
After undergoing a promising new treatment for acute lymphoblastic leukemia (ALL), Cole Malone is back to doing what he loves: playing on a flag football team with his twin brother, Michael. Cole and Michael Malone, who are 14, already know plenty about teamwork. Michael served as a perfect-match donor when Cole underwent a stem cell … Continued
In early 2018, Sandra Linberg received an infusion of CAR T cells only a few months after the therapy was approved for treating her type of cancer. After only a month, her lymphoma had completely disappeared – she was in a complete remission. “Those little warrior cells took care of it,” declared Linberg, who has continued … Continued
A year ago, Kelly Lamphere’s multiple myeloma was not responding to treatment, and her legs were so weakened by the cancer in her bones that she relied on a wheelchair and a walker. Today, because of CAR T-cell therapy, Lamphere’s disease is under control—and she can walk unaided again.
CAR T-cell therapy—a form of immunotherapy that uses genetically engineered T cells to intensify the immune system’s response to cancer—represents one of the biggest advances against cancer in recent years.
CAR T-cell therapy uses specially altered T cells — which are part of the body’s immune system — to fight cancer.
Boston-based researchers hope to optimize CAR T-cell therapies to target DIPG, aggressive and difficult-to-treat brain tumors, and other tough-to-treat cancers.
Gene therapy is a way of treating or preventing disease by altering the genetic instructions within an individual’s cells.
CAR T-cell therapy is a form of immunotherapy that uses specially modified T cells – part of the body’s defense system against disease – to attack cancer. This therapy has proven strikingly successful for some patients with certain forms of blood cancer. As of May 2018, CAR T-cell therapy has been approved by the U.S. Food and … Continued
“Living” drugs consist of fully functional cells that have been selected and often modified to treat specific diseases, such as cancer. CAR T-cell therapy and therapeutic vaccines fall into this category.
The word “refractory” in general use means stubborn or intractable, and in medicine it is specifically applied to disease that does not respond to treatment. Refractory cancer refers to cancer that may be resistant at the beginning of treatment, or becomes resistant during treatment. “We would consider disease refractory if doesn’t respond at all or … Continued
There are many types of gene therapy, but all of them involve adding to or modifying the genetic program in a person – his or her DNA blueprint that provides instructions for building and operating the body. Gene therapy technology has been developed over several decades and has been successfully used to correct rare blood … Continued
CAR T-cell therapy is a cancer treatment in which a patient’s immune system T cells are genetically modified to mount a more effective attack on cancer. As of May 2018, CAR T-cell therapy has been approved by the U.S. Food and Drug Administration as standard therapy for some adult patients with aggressive non-Hodgkin lymphoma that has relapsed after … Continued
In 1947, when Dana-Farber Cancer Institute founder Sidney Farber, MD, set out to find a drug treatment for childhood leukemia, cancer treatment took two forms – surgery to cut out cancerous masses, and radiation therapy to burn them out. Cancers that couldn’t be removed or irradiated – either because of their position in the body, because … Continued
CAR T-cell therapy, like all forms of cancer immunotherapy, seeks to sharpen and strengthen the immune system’s inherent cancer-fighting powers. It involves treating patients with modified versions of their own immune system T cells – white blood cells that help protect the body from disease. The groundbreaking therapy recently became the first of its kind … Continued
A drug called Axicabtagene ciloleucel (KTE-C19) has become the first chimeric antigen receptor (CAR) T-cell therapy approved to treat a form of cancer in adults, the Food and Drug Administration (FDA) announced today. The decision means the drug, known as Yescarta, can now be used for some adults with refractory aggressive non-Hodgkin lymphoma (NHL). The FDA ruling in … Continued
Non-Hodgkin lymphoma is one of the two major subtypes of lymphoma, and about 72,000 people will be diagnosed with this cancer by the end of 2017, according to the American Cancer Society. There are more than 50 types of non-Hodgkin lymphoma – including B-cell and T-cell lymphomas, as well as fast-growing and slow-growing lymphomas. There … Continued